On the y axis, the transcript intensity in tumors
is shown, and on the x axis the transcript intensity in
matched normal biopsies is shown. Intensities are measured as a relative
fluorescence unit (RFU) signal as assessed with Agilent microarray
technology. Overexpression in the tumor is denoted in turquoise points,
underexpression is denoted in red and no change is denoted in black. The
twofold threshold (both high and low) is indicated by two dotted black
lines. All 101 patients of the WINTHER study with evaluable RNA data were
considered. Example 1 shows a patient with a low level of basal expression
(300 RFU) in the tumor and 300 RFU in the normal biopsies, with no
differential expression between the normal and tumor biopsies. Example 2
shows a patient with a high level of basal expression of 6,000 RFU in the
tumor versus 6,000 RFU in the normal biopsies, but again no differential
expression between the tumor and normal counterpart. Example 3 marked in
turquoise shows the pattern of a higher expression in tumor versus normal
tissue. Example 4 marked in red shows the pattern of a lower expression in
tumor versus normal tissue. This current study hypothesizes that
simultaneously investigating the matched phenotypically normal tissue can
help to optimize transcriptomic data. With this approach, each patient
serves as his or her own control, hence avoiding the use of pooled tumor or
normal tissues. Our data demonstrate that the level of basal gene expression
is highly variable between individuals. All patients presented with black
points had no differential expression between tumor and normal tissue, but
others show a large variability between individuals in the basal level of
normal expression of VEGFA.